163 related articles for article (PubMed ID: 36752369)
1. Imaging of Small-Bowel Neuroendocrine Neoplasms:
Navin PJ; Ehman EC; Liu JB; Halfdanarson TR; Gupta A; Laghi A; Yoo DC; Carucci LR; Schima W; Sheedy SP
AJR Am J Roentgenol; 2023 Sep; 221(3):289-301. PubMed ID: 36752369
[TBL] [Abstract][Full Text] [Related]
2. Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response-
Galgano SJ; Iravani A; Bodei L; El-Haddad G; Hofman MS; Kong G
AJR Am J Roentgenol; 2022 May; 218(5):767-780. PubMed ID: 34985313
[TBL] [Abstract][Full Text] [Related]
3. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.
Saleh M; Bhosale PR; Yano M; Itani M; Elsayes AK; Halperin D; Bergsland EK; Morani AC
Abdom Radiol (NY); 2022 Sep; 47(9):3078-3100. PubMed ID: 33095312
[TBL] [Abstract][Full Text] [Related]
4. NEN - the role of somatostatin receptor scintigraphy in clinical setting.
Opalińska M; Hubalewska-Dydejczyk A; Sowa-Staszczak A; Stefańska A
Nucl Med Rev Cent East Eur; 2016; 19(2):118-25. PubMed ID: 27479789
[TBL] [Abstract][Full Text] [Related]
5. Comparison of [
Chen D; Yang S; Chen J; Li T; Liu Y; Zhao X; Zhang T; Xu M; Wang H; Zhao K; Su X
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2420-2431. PubMed ID: 36971805
[TBL] [Abstract][Full Text] [Related]
6. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
7. PET/MRI imaging in neuroendocrine neoplasm.
Virarkar MK; Montanarella M; Itani M; Calimano-Ramirez L; Gopireddy D; Bhosale P
Abdom Radiol (NY); 2023 Dec; 48(12):3585-3600. PubMed ID: 36525051
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
9. Preoperative
Norlén O; Montan H; Hellman P; Stålberg P; Sundin A
World J Surg; 2018 Feb; 42(2):498-505. PubMed ID: 29159606
[TBL] [Abstract][Full Text] [Related]
10. [
Giovannini E; Giovacchini G; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Ciarmiello A
Curr Radiopharm; 2019; 12(1):11-22. PubMed ID: 30539709
[TBL] [Abstract][Full Text] [Related]
11. Limited role of carbidopa-assisted
Imperiale A; Averous G; Helali M; Taieb D; Pessaux P; Goichot B; Addeo P; Bachellier P
Ann Nucl Med; 2019 Sep; 33(9):697-707. PubMed ID: 31214959
[TBL] [Abstract][Full Text] [Related]
12. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
13. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
14. Role of positron emission tomography in thyroid and neuroendocrine tumors.
Treglia G; Kroiss AS; Piccardo A; Lococo F; Santhanam P; Imperiale A
Minerva Endocrinol; 2018 Sep; 43(3):341-355. PubMed ID: 28949122
[TBL] [Abstract][Full Text] [Related]
15. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
[TBL] [Abstract][Full Text] [Related]
16. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
17. PET/CT and PET/MRI in neuroendocrine neoplasms.
Rajamohan N; Khasawneh H; Singh A; Suman G; Johnson GB; Majumder S; Halfdanarson TR; Goenka AH
Abdom Radiol (NY); 2022 Dec; 47(12):4058-4072. PubMed ID: 35426497
[TBL] [Abstract][Full Text] [Related]
18. Added value of [
Yoo J; Kim SH; Jeon SK; Bae JS; Han JK
Eur Radiol; 2021 Oct; 31(10):7734-7745. PubMed ID: 33787974
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
20. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]